{ }
Very Negative
Negative
Neutral
Positive
Very Positive
2025-04-072025-04-072025-04-082025-04-082025-04-092025-04-092025-04-102025-04-102025-04-112025-04-112025-04-132025-04-13213211124433221100
Download SVG
Download PNG
Download CSV
Somewhat Relevant
Moderately Relevant
Very Relevant
Highly Relevant
2025-04-072025-04-072025-04-082025-04-082025-04-092025-04-092025-04-102025-04-102025-04-112025-04-112025-04-132025-04-13111222314433221100
Download SVG
Download PNG
Download CSV

ubs maintains buy rating for essilorluxottica with target price of 232 euros

UBS has maintained a 'Buy' rating for EssilorLuxottica, setting a target price of 232 euros, following the eyewear group's quarterly sales figures. Analyst Robert Krankowski expressed concerns about the disappointing results, which may impact the anticipated margin increase in the second half of the year. As of the latest trading, EssilorLuxottica's stock was down 1.25% at €213.60.
19:25 17.10.2024

UBS rates EssilorLuxottica as buy with target price of 232 euros

UBS has assigned a "buy" rating to EssilorLuxottica with a target price of 232 euros following the eyewear group's quarterly sales figures. Analyst Robert Krankowski noted that the disappointing results raise concerns about the anticipated margin increase in the second half of the year.
19:25 17.10.2024

healthcare fraud analytics market projected to reach 17.7 billion by 2030

The global Healthcare Fraud Analytics market, valued at $4.0 billion in 2023, is projected to reach $17.7 billion by 2030, growing at a CAGR of 23.6%. Key drivers include rising healthcare fraud, regulatory pressures, and advancements in AI and machine learning, enhancing fraud detection capabilities. The market is increasingly adopting cloud-based solutions for their scalability and cost-effectiveness, with significant growth expected in both descriptive and predictive analytics segments.

ubs lowers puma price target amid stock market challenges

UBS has reduced its price target for Puma SE from 48.50 to 43.50 euros, maintaining a "Neutral" rating as the stock trades at 39.01 euros, down 0.54% from the previous day. Despite this, Puma's shares have risen 4.34% over the past month, with a market capitalization of €5.9 billion and a planned dividend of €0.82 per share for 2024, yielding 1.72%. Investors are urged to consider their positions in light of the latest analysis indicating a need for action.
17:16 17.10.2024

abbott laboratories receives buy rating from ubs amid strong product sales

Abbott Laboratories, a leader in pharmaceutical and medical product development, has received a Buy rating from UBS. The company's net sales are primarily derived from diagnostic systems (39.1%) and vascular devices (24.7%), with significant contributions from nutritional products (12.1%) and medical products (8.2%). Geographically, the United States accounts for 38.5% of sales, followed by Germany (5.8%) and China (5.6%).
17:14 17.10.2024

walgreens boots alliance maintains neutral rating amid diverse sales distribution

Walgreens Boots Alliance, Inc. focuses on pharmaceutical product distribution, with net sales primarily from retail distribution (87.2%), including prescription and over-the-counter drugs, and beauty products. The company operates 13,532 points of sale, predominantly in the U.S., and generates 84% of its sales domestically. Wholesale distribution accounts for 8.1% of sales, while the healthcare sector contributes 4.7%.
17:13 17.10.2024

walgreens boots alliance maintains neutral rating amid diverse sales distribution

Walgreens Boots Alliance, Inc. focuses on pharmaceutical product distribution, with net sales primarily from retail distribution (87.2%), including prescription and over-the-counter drugs, and beauty products. The company operates 13,532 points of sale, predominantly in the U.S., and generates 84% of its sales domestically, with additional revenue from wholesale distribution (8.1%) and the healthcare sector (4.7%).
17:13 17.10.2024

us healthcare system ranks last in access equity and outcomes

The U.S. healthcare system ranks last among 10 countries in access, equity, and outcomes, despite spending over 16% of its GDP on healthcare. Key issues include high costs, a fragmented insurance system, and significant numbers of uninsured and underinsured individuals, leading to poor health outcomes and limited access to care. Recommendations for improvement include extending coverage to the uninsured, reducing administrative complexity, and investing in public health.

ecb cuts interest rates again amid economic concerns and inflation challenges

The European Central Bank (ECB) has cut its key interest rates for the third time since June, with the deposit rate now at 3.25% and the main refinancing rate at 3.40%. This decision comes amid economic distress and weak manufacturing indicators, although the ECB maintains a soft landing outlook for the economy. Future rate cuts are anticipated, influenced by ongoing wage demands in the service sector, which could keep rates higher than pre-pandemic levels.
16:47 17.10.2024

ubs maintains neutral rating for nokia with target price of 3.55 euros

UBS has maintained a 'Neutral' rating for Nokia, setting a price target of 3.55 euros following the company's third-quarter results, which fell short of sales expectations. While the operating result met forecasts due to a favorable product mix and cost-cutting, the analyst anticipates a slight decline in consensus estimates for the operating result due to more pessimistic annual targets.
16:06 17.10.2024
Trending
Subcategory
Countries:
Companies:
Currencies:
People:

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Address

Newsletter

© 2025 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.